 This is a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose, pilot Phase 2a study in anemic stage 5 chronic kidney disease patients requiring hemodialysis. Eligible patients will undergo screening assessments and PRS-08022-DP will be administered by intravenous infusion. The study will consist of 2 dose cohorts of 4 mgkg and 8 mgkg body weight with 6 patients in each cohort. Using a standard 42 design, 4 patients in each cohort will be randomized to PRS-080022-DP and 2 patients in each cohort will be randomized to placebo. The decision to escalate the dose will be based on an interim analysis of clinical and laboratory safety as well on a comparison with pharmacokinetic data. Safety and tolerability, pharmacokinetics, pharmacodynamics as well as potential immunogenicity will be investigated. 